U.S. track star Noah Lyles takes bronze in 200-meter, says he tested positive for Covid

U.S. track star Noah Lyles takes bronze in 200-meter, says he tested positive for Covid


Botswana’s Letsile Tebogo, US’ Kenneth Bednarek and US’ Noah Lyles cross the finish line to finish first, second and third respectively in the men’s 200m final of the athletics event at the Paris 2024 Olympic Games at Stade de France in Saint-Denis, north of Paris, on August 8, 2024.

Odd Andersen | AFP | Getty Images

PARIS — Two days after Noah Lyles said he tested positive for Covid, the American sprinter finished third in the 200-meter final at the Paris Olympics, unable to chase down gold medalist Letsile Tebogo of Botswana. 

Lyles ran 19.70 for bronze, behind Tebogo’s 19.46, which earned the first gold medal in Botswana’s history. American Kenny Bednarek earned silver in 19.62.

Following his positive test, Lyles said he moved into a hotel away from the Olympic Village to quarantine himself and arrived for warmups before Wednesday’s semifinal with a mask on. He said he never considered not competing in Thursday’s final and intentionally did not disclose information about his diagnosis.

“You never want to tell your competitors you’re sick,” he said. “Why would you give them an edge over you?”

Lyles, 27, appeared his usual energetic self when he was introduced before the final, jumping and sprinting down the track before getting into his blocks as a sold-out crowd inside Stade de France grew silent. Lyles was running from behind right from the start, looking little like the sprinter who had won 26 consecutive races dating to 2021 until he finished second in Wednesday’s semifinal — also to Tebogo — and had been 38-5 all-time against the seven other sprinters in Thursday’s final. 

At the finish line Lyles collapsed, then gingerly stood while asking for water and sitting back down on the track. He was put into a wheelchair and carted off underneath the stadium. It was a stark contrast to Sunday night, when Lyles won the first Olympic gold medal of his career by winning the 100-meters by five-thousandths of a second and afterward guaranteed that he would win the 200 meters, as well. 

US’ Noah Lyles reacts after competing in the men’s 200m final of the athletics event at the Paris 2024 Olympic Games at Stade de France in Saint-Denis, north of Paris, on August 8, 2024. 

Jewel Samad | AFP | Getty Images

Testing positive for COVID “definitely affected my performance,” Lyles said. “But I mean, to be honest, I’m more proud of myself than anything coming out and get the bronze medal with COVID in three days. It’s been a wild Olympics.”

In a statement, USA Track & Field said that it and the U.S. Olympic committee had adhered to guidelines set by the Centers for Disease Control and the International Olympic Committee to “prioritize his health, the wellbeing of our team, and the safety of fellow competitors.” 

“Our primary commitment is to ensure the safety of Team USA athletes while upholding their right to compete. After a thorough medical evaluation, Noah chose to compete tonight. We respect his decision and will continue to monitor his condition closely.”

Lyles was attempting to become the first man to sweep both sprints at an Olympics since Jamaica’s Usain Bolt in 2016, and the first from the U.S. since Carl Lewis 40 years ago. Earning bronze also ends Lyles’s much-discussed ambition of becoming the first track athlete to win four gold medals at a single Olympics since 1984.

He said he would let USA Track & Field decide whether he should run on the U.S. 4×100-meter relay team that qualified for Friday’s final with the fastest time in preliminaries.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More